342P QOL analysis of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second line or above therapy in recurrent head and neck cancer
In Annals of Oncology
By: Chanana R.
Contributor(s): Noronha V | Joshi A | Patil V | Dhumal S | Bhattacharya A | Chandrasekharan A | Pande N | Talreja VT | Turkar S | Shrirangwar S | Prabhash K.
Material type:
ArticlePublisher: 2017Description: .Subject(s): Head and neck cancer | QOL | Cabazitaxel | Docetaxel
In:
Annals of OncologySummary: Background: Cabazitaxel has shown activity in squamous cancer cell lines and in taxane resistant cell lines. We reported a randomized phase 2 study to evaluate the efficacy and safety of cabazitaxel against docetaxel in recurrent head and neck cancer, post first line treatment. The previously reported outcome of this study reported Docetaxel had a superior disease control rate at 6 weeks (52.3% versus 13.6%, p = 0.017) OS (155 vs 115 days) compared to cabazitaxel. In this analysis we planned to compare the QOL between the 2 arms.
Methods: This was a phase 2 open-label, investigator-initiated, randomized controlled trial of Docetaxel (75 mg/m2) versus Cabazitaxel (20 mg/m2), in adult patients with head and neck cancer, ECOG performance status 0-2, with measurable disease, who...
| Item type | Current location | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|
Articles
|
Tata Memorial Hospital | Available | AR18669 |
Background: Cabazitaxel has shown activity in squamous cancer cell lines and in taxane resistant cell lines. We reported a randomized phase 2 study to evaluate the efficacy and safety of cabazitaxel against docetaxel in recurrent head and neck cancer, post first line treatment. The previously reported outcome of this study reported Docetaxel had a superior disease control rate at 6 weeks (52.3% versus 13.6%, p = 0.017) OS (155 vs 115 days) compared to cabazitaxel. In this analysis we planned to compare the QOL between the 2 arms.
Methods: This was a phase 2 open-label, investigator-initiated, randomized controlled trial of Docetaxel (75 mg/m2) versus Cabazitaxel (20 mg/m2), in adult patients with head and neck cancer, ECOG performance status 0-2, with measurable disease, who...
There are no comments for this item.